Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Efficacy and safety of ABiC in primary open-angle glaucoma (POAG) over a 24 month period

Poster Details

First Author: M.Khaimi USA

Co Author(s):                        

Abstract Details


To investigate the efficacy and safety of ABiC alone and combined cataract surgery-ABiC in reducing IOP and medication use in mild-to-moderate primary open angle glaucoma (POAG).


University of Oklahoma, Dean McGee Eye Institute, Oklahoma, USA


This was a single center, prospective, nonrandomized study exploring the efficacy and safety of ABiC or combined cataract surgery-ABiC in adult patients with mild-to-moderate POAG. Primary endpoints were mean IOP and mean number of glaucoma medications over a 24-month period.


In 83 patients (71.0 ±10.2 years), 26 patients who underwent standalone ABiC saw reduction in mean IOP and medications from 20.7 ±5.9 mmHg and 2.1 ±1.0 preoperatively to 16.9 ±3.3 mmHg (18.4% reduction, p=0.002) and 0.9 ±0.9 (47.7% reduction, p=0.002). In 57 patients who underwent combined cataract and ABiC, mean IOP and medications reduced from 17.9 ±5.2 mmHg and 1.9 ±0.9 to 15.6 ±2.2 mmHg (12.8% reduction, p=0.005) and 0.4 ±0.7 (83.1% reduction, p<0.001). Fourteen-percent saw an IOP reduction greater than 20%. By 24 months 39% of patients with standalone ABiC and 29% with combined ABiC saw this reduction.


ABiC is an effective treatment option for patients with primary open-angle glaucoma to both reduce IOP and eliminate medication. ABiC combined with cataract might further reduce glaucoma medications.

Financial Disclosure:


Back to Poster listing